Should You Buy Eli Lilly Stock Before Oct. 30?

Core Insights - Eli Lilly has been a prominent player in the pharmaceutical sector but has faced challenges in 2025, with expectations for a turnaround in Q3 results [1] Group 1: Wall Street Expectations - Analysts predict Q3 revenue for Eli Lilly to be approximately $16 billion, reflecting a year-over-year increase of 40.5% [2] - The average earnings per share (EPS) estimate for Q3 is $5.92, with a range from a pessimistic $5.49 to an optimistic $7.21, indicating significant growth from the $1.18 EPS reported in Q3 2024 [3] Group 2: Growth Drivers - Key products driving growth include the Type 2 diabetes drug Mounjaro and the obesity drug Zepbound, which together account for around 55% of total revenue [4] Group 3: Stock Performance Trends - Historical performance shows that even when Eli Lilly beats analyst estimates, stock reactions can be unpredictable, as seen in the last four quarters where the stock did not consistently respond as expected [5][6] - Despite beating EPS estimates in Q4 2024, the stock initially gained but quickly lost those gains, while a miss in Q1 2025 did not lead to a decline in stock price [6] Group 4: Long-term Perspective - Analysts suggest maintaining a long-term investment perspective with Eli Lilly, as short-term stock movements may not align with earnings performance [7]